Reading room

Research peptides: questions & evidence.

Read focused questions about BPC-157, GH-release pathways, copper complexes, MOTS-c and Epitalon. Keep cell, animal and human evidence distinct, examine combination claims, and separate Canadian product rules from anti-doping requirements.

Reset filters

Guides in this topic

1–10 of 10 guides

Page 1 of 1
Gut models are specific experiments. Drug-induced injury: An experimental trigger; Ischemia / reperfusion: Blood-flow injury model; Human condition: Needs diagnosis-specific evidence.Research Practice

BPC-157 and Gut Research: Injury Models, Colitis and Human Evidence Gaps

BPC-157 gut research spans several experimental injury models, especially in rats. A result in a chemically induced lesion or blood-flow injury model is not the same as evidence for treating a human digestive diagnosis.

Updated 2026-11-06 ↗
Tendon evidence: model to outcome. Cell migration: Laboratory behaviour; Tendon tissue: Model-specific observations; Human recovery: A separate clinical question.Research Practice

BPC-157 Tendon Research: Cell Migration Is Not a Human Recovery Time

BPC-157 tendon research includes laboratory studies of tendon explants and fibroblasts. These experiments investigate biological mechanisms.

Updated 2026-11-06 ↗
CJC-1295: match the studied molecule. Label and alias: Request the complete identity; Molecular modification: Part of the specification; Published study: Transfer only matching evidence.Documentation & Traceability

CJC-1295 DAC vs “No DAC”: Identity Comes Before the Half-Life Claim

CJC-1295 DAC vs no DAC is first an identity question. A supplier’s alias is not enough to establish that two products are the same molecule or share a pharmacokinetic profile.

Updated 2026-11-06 ↗
Telomere change is a cell endpoint. Cell-line assay: A defined biological model; Telomere measurement: A molecular endpoint; Human longevity: A separate clinical claim.Research Practice

Epitalon and Telomeres: Why Cell-Line Findings Do Not Prove Human Longevity

Epitalon and telomeres are linked in laboratory research, but a cell-line result is not proof of longer human life. Telomere length, telomerase-related activity and alternative lengthening pathways are biological measurements.

Updated 2026-11-06 ↗
GHK-Cu / AHK-Cu. GHK: Glycine · histidine · lysine; AHK: Alanine · histidine · lysine; Evidence: Match the complex and model.Peptide Fundamentals

GHK-Cu vs AHK-Cu: One Amino Acid, Different Experimental Evidence

GHK-Cu vs AHK-Cu starts with a sequence difference: glycine in GHK and alanine in AHK. Both names describe copper-associated tripeptides, but a shared metal and similar letters do not make their experimental evidence interchangeable.

Updated 2026-11-06 ↗
GH release: different interventions. Ipamorelin: GHRP-like receptor research; GHRH-(1–29): A GHRH-fragment intervention; Measured endpoint: GH and IGF-I response.Peptide Fundamentals

Ipamorelin vs Sermorelin: Different GH-Release Pathways and Evidence

Ipamorelin vs sermorelin compares different approaches to stimulating growth-hormone release. The shared hormonal endpoint does not make the molecules, receptor pathways or evidence interchangeable.

Updated 2026-11-06 ↗
Two different MOTS-c experiments. Human exercise: Measure endogenous expression; Mouse intervention: Administer a defined material; Clinical claim: Needs a human intervention trial.Research Practice

MOTS-c and Exercise: Endogenous Human Responses vs Peptide Administration

MOTS-c and exercise research contains two observations that are often merged incorrectly. Measuring an endogenous peptide after exercise in people is different from administering a peptide to mice and measuring performance.

Updated 2026-11-06 ↗
Peptide risk is product-specific. Molecule: Biological effects; Product: Manufacture and formulation; Evidence: Population and follow-up.Research Practice

Peptide Side Effects: Why the Exact Molecule, Product and Evidence Matter

Peptide side effects depend on the exact molecule, finished product, route and person studied. The word peptide covers a broad chemical category.

Updated 2026-11-06 ↗
Combination evidence needs comparisons. Ingredient A: Its own evidence; Ingredient B: Its own evidence; A + B: A separate intervention.Research Practice

Peptide Stacks: Why Evidence for Two Ingredients Does Not Prove a Combination

Peptide stacks are combinations, and a combination is a new evidence question. Two ingredients with separate studies do not automatically produce demonstrated synergy, a known safety profile or a predictable clinical outcome when combined.

Updated 2026-11-06 ↗
Two separate rule systems. Health-product record: Canadian product authorization; Anti-doping rules: Substance and sport context; Date: Use the applicable annual list.Research Practice

Peptides and WADA in Canada: Product Approval Is Not Anti-Doping Permission

Peptides and WADA require a separate check from Canadian medicine authorization. A product can have a medical use while still being subject to sport restrictions, and a research-use label does not provide anti-doping permission.

Updated 2026-11-06 ↗

Explore the related peptide dossiers

Research Peptides: Safety, Models & Evidence | PeptideTwo